<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498444</url>
  </required_header>
  <id_info>
    <org_study_id>33852</org_study_id>
    <nct_id>NCT02498444</nct_id>
  </id_info>
  <brief_title>Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation</brief_title>
  <official_title>Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the efficacy of treprostinil in the perioperative&#xD;
      non-fenestrated, extracardiac Fontan patients in order to reduce duration of chest tube&#xD;
      drainage (in days).&#xD;
&#xD;
      The Fontan operation is performed for patients with single ventricle physiology as the final&#xD;
      palliation to create a series circulation, with passive systemic venous return to the&#xD;
      pulmonary arteries and the single ventricle solely providing systemic output.&#xD;
&#xD;
      Patients undergoing extracardiac Fontan tend to have elevation of Fontan pressures&#xD;
      immediately following the operation with inflammation from surgery requiring additional fluid&#xD;
      administration to maintain blood pressure. Increased Fontan pressures and fluid overload lead&#xD;
      to prolonged chest tube drainage.&#xD;
&#xD;
      The hypothesis is that treprostinil, a prostacyclin drug that dilates the pulmonary arteries,&#xD;
      will improve immediate postoperative Fontan pressures. Treprostinil is not FDA approved for&#xD;
      this use. Anecdotally and in a small case series, prostacyclin therapy has been shown to&#xD;
      assist in transitioning patients off nitric oxide. The investigators believe that this&#xD;
      improvement in hemodynamics will decrease duration of chest tube drainage resulting in a&#xD;
      shorter length of hospital stay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to understand the effect of treprostinil on Fontan patients, this study has two&#xD;
      parts:&#xD;
&#xD;
        1. reactivity testing with inhaled treprostinil in the cardiac catheterization lab for&#xD;
           pre-Fontan patients undergoing routine catheterization in anticipation of the Fontan&#xD;
           operation;&#xD;
&#xD;
        2. perioperative use of subcutaneous treprostinil starting immediately pre-op until&#xD;
           postoperative day #7 to improve immediate postoperative hemodynamics and ultimately&#xD;
           reduce overall length of hospital stay.&#xD;
&#xD;
      The investigators hope to learn how pulmonary vasodilator therapy affects and/or improves&#xD;
      post- operative hemodynamics following the Fontan operation. This knowledge would be very&#xD;
      important in the care of single ventricle patients following the Fontan operation if there is&#xD;
      improvement of immediate outcomes and reduction of hospital length of stay. On a broader&#xD;
      scale, if the use of treprostinil in perioperative Fontan patients can achieve the same&#xD;
      results other centers achieve with the use of a fenestration this may have wide scale&#xD;
      implications in the nationwide treatment of Fontan patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chest tube duration</measure>
    <time_frame>2-3 wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>2-3 wks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Single Ventricle</condition>
  <arm_group>
    <arm_group_label>Treprostinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline administration via subcutaneous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treprostinil</intervention_name>
    <description>Administration of drug (treprostinil) vs placebo (saline) in the post-operative period</description>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_label>Treprostinil</arm_group_label>
    <other_name>Remodulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patient undergoing Fontan operation and/or pre-Fontan cardiac&#xD;
             catheterization at Lucile Packard Children's Hospital (LPCH)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Platelet count &lt; 50K (treprostinil can act as a platelet inhibitor and this may place&#xD;
             patient at additional risk of bleeding if already thrombocytopenic)&#xD;
&#xD;
          -  Dermatologic condition that renders the patient unable to tolerate a subcutaneous&#xD;
             infusion (can still take part in inhaled vasodilator testing during cardiac&#xD;
             catheterization)&#xD;
&#xD;
          -  Currently receiving any vasodilator therapy specifically for the purpose of pulmonary&#xD;
             vsasodilation (phosphodiesterase type 5 inhibitor, endothelia receptor antagonist&#xD;
             and/or prostacyclin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Feinstein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital, Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Handler SS, Ogawa MT, Hopper RK, Sakarovitch C, Feinstein JA. Subcutaneous treprostinil in pediatric patients with failing single-ventricle physiology. J Heart Lung Transplant. 2017 Sep 14. pii: S1053-2498(17)31993-9. doi: 10.1016/j.healun.2017.09.008. [Epub ahead of print]</citation>
    <PMID>29126699</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jeffrey A. Feinstein</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Fontan</keyword>
  <keyword>Treprostinil</keyword>
  <keyword>Remodulin</keyword>
  <keyword>Single ventricle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Univentricular Heart</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

